PubMed

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M.

Ann Intern Med. 2003 Aug 19;139(4):258-66.PMID: 12965981 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. Does marijuana affect viral loads in people with HIV?

[No authors listed]

Ann Intern Med. 2003 Aug 19;139(4):I44. No abstract available. PMID: 12965999 [PubMed - indexed for MEDLINE]Related articlesFree article

The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.

Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI.

AIDS. 2002 Mar 8;16(4):543-50.PMID: 11872997 [PubMed - indexed for MEDLINE]Related articles

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.PMID: 15097300 [PubMed - indexed for MEDLINE]Related articles

Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 x 10(6)/l.

García F, Vidal C, Gatell JM, Miró JM, Soriano A, Pumarola T.

AIDS. 1997 Jan;11(1):53-7.PMID: 9110075 [PubMed - indexed for MEDLINE]Related articles

Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.

Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, Poli G, Gotch F, Autran B.

Antivir Ther. 2007;12(4):553-8.PMID: 17668564 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.

Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.

Antivir Ther. 2005;10(8):911-6.PMID: 16430196 [PubMed - indexed for MEDLINE]Related articles

Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals.

Weber R, Christen L, Loy M, Schaller S, Christen S, Joyce CR, Ledermann U, Ledergerber B, Cone R, Lüthy R, Cohen MR.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):56-64.PMID: 10534147 [PubMed - indexed for MEDLINE]Related articles

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.

Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R; California Collaborative Treatment Group #575 Team.

AIDS. 2001 Mar 30;15(5):609-15.PMID: 11316998 [PubMed - indexed for MEDLINE]Related articles

HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

Lucia MB, Rutella S, Leone G, Vella S, Cauda R.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):321-30.PMID: 11468419 [PubMed - indexed for MEDLINE]Related articles

Effect of the serotonin receptor agonist, buspirone, on immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial.

Eugen-Olsen J, Benfield T, Axen TE, Parner J, Iversen J, Pedersen C, Nielsen JO.

HIV Clin Trials. 2000 Jul-Aug;1(1):20-6.PMID: 11590486 [PubMed - indexed for MEDLINE]Related articlesFree article

Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire.

Koblavi-Dème S, Kestens L, Hanson D, Otten RA, Borget MY, Bilé C, Wiktor SZ, Roels TH, Chorba T, Nkengasong JN.

AIDS. 2004 Feb 20;18(3):413-9.PMID: 15090792 [PubMed - indexed for MEDLINE]Related articles

Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).

Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F; ANRS 109 VISTA Study Group.

Antivir Ther. 2006;11(7):889-99.PMID: 17302251 [PubMed - indexed for MEDLINE]Related articles

Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection.

Jariwalla RJ, Lalezari J, Cenko D, Mansour SE, Kumar A, Gangapurkar B, Nakamura D.

J Altern Complement Med. 2008 Mar;14(2):139-46.PMID: 18315507 [PubMed - indexed for MEDLINE]Related articles

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration.

Lancet. 2004 Jul 3-9;364(9428):51-62.PMID: 15234856 [PubMed - indexed for MEDLINE]Related articles

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.PMID: 16941337 [PubMed - indexed for MEDLINE]Related articles

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients]

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese. PMID: 18261327 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team.

Lancet. 2007 Apr 14;369(9569):1261-9.PMID: 17434401 [PubMed - indexed for MEDLINE]Related articles

A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.

Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC.

AIDS. 2000 Nov 10;14(16):2503-8.PMID: 11101061 [PubMed - indexed for MEDLINE]Related articles

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Lancet. 2006 Dec 16;368(9553):2125-35.PMID: 17174704 [PubMed - indexed for MEDLINE]Related articles